Ignite Creation Date:
2024-05-06 @ 4:10 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04896606
Status:
RECRUITING
Last Update Posted:
2023-10-26
First Post:
2021-05-19
Brief Title:
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease
Sponsor:
New York Medical College
Organization:
New York Medical College
Study Overview
Official Title:
A Pilot Study of SARS-CoV-2 Specific Cytotoxic T Lymphocytes SARS-CoV-2-CTLs for Treatment of Mild to Moderate Coronavirus Disease 2019 COVID-19
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The 2019 Severe Acute Respiratory Syndrome SARS is a global pandemic secondary to a novel coronavirus - SARS-CoV-2 The reported case-fatality ratio for SARS-CoV-2 in the United States is 18 with a current death toll of 300000 and climbing4 There is no accepted standard of care or FDA approved therapies for treatment of COVID-19 Virus specific cytotoxic T lymphocytes CTLs have become an important part of the treatment landscape for viral reactivation post hematopoietic and solid organ transplantation Donor derived CTLs have been shown to be safe and effective against a variety of viruses including CMV EBV BK and adenovirus We hypothesize that SARS-CoV-2 specific CTLs generated from a previously infected family donor will be safe and effective for treatment of COVID-19 in family members with mild to moderate disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None